Collagen Peptides Side Effects: What Studies Report

Collagen peptides — described in the published literature as hydrolysed collagen, collagen hydrolysate, or low-molecular-weight collagen peptide (LMWCP) — have been examined mainly in randomised, double-blind, placebo-controlled trials of skin and joint outcomes. In most of those trials, efficacy was the primary question and tolerability was recorded alongside it. This page summarises what those published reports stated about adverse events, what they measured, and where the safety record is thin. A separate PeptideU learning course covers how collagen peptides were studied and what the efficacy findings looked like; this page stays on the safety and tolerability question.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any supplement, medication, or health condition.

How safety was assessed in collagen peptide trials

Understanding the reported side-effect picture requires knowing how it was collected. In the skin trials, participants were typically healthy adult volunteers followed for a defined supplementation period, with instrument-based skin measurements as the primary endpoints and adverse events logged as a secondary observation. For example, researchers in a double-blind, placebo-controlled study administered 2.5 g or 5.0 g of specific bioactive collagen peptides daily for 8 weeks and reported improvements in skin elasticity relative to placebo (Skin Pharmacology and Physiology, 2014). A separate randomised, double-blind, placebo-controlled study gave 1,000 mg of low-molecular-weight collagen peptide daily for 12 weeks and reported improvements in skin hydration, elasticity and wrinkling (Nutrients, 2018).

Trials of this design detect common, obvious complaints — nausea, bloating, headache, rash — because participants are asked about them at scheduled visits. They are not designed to detect rare events, delayed events, or effects that appear only after years of continuous intake. That distinction matters when interpreting statements that a study "reported no adverse events": such a statement describes the sample and the follow-up window, not the compound in general.

Tolerability in skin trials: What Studies Report

The broadest summary of dermatological data comes from a systematic review of oral collagen supplementation for skin applications, in which the authors pooled randomised trials and reported that no adverse events were recorded across the included studies (Journal of Drugs in Dermatology, 2019). Individual trials published since have been consistent with that summary in the sense that their published reports centred on efficacy outcomes rather than on safety signals.

A randomised, double-blinded, placebo-controlled study of a low-molecular-weight collagen peptide supplement reported improvements in skin parameters in the supplemented group (Journal of Cosmetic Dermatology, 2024). Another randomised, double-blinded, placebo-controlled study of oral collagen peptide NS reported improvements in hydration, elasticity, desquamation and wrinkling in human skin (Food & Function, 2023). Researchers in a further randomised, double-blinded, placebo-controlled study of oral low-molecular-weight collagen peptides reported reduced skin wrinkles and improved biophysical properties of skin (Journal of Medicinal Food, 2022), and a more recent randomised, double-blind, placebo-controlled clinical trial in healthy adults reported skin anti-aging and moisturising effects (Journal of Microbiology and Biotechnology, 2025). In each case the published abstract framed the finding as an efficacy outcome in healthy volunteers over a fixed study period; none of these reports described a pattern of treatment-limiting side effects.

What "no adverse events" did and did not mean

• It described the participants enrolled — generally healthy adults, often women, recruited for cosmetic skin endpoints.
• It described the follow-up window used in that trial, not open-ended use.
• It did not establish that the product tested is interchangeable with other collagen preparations, which differ by source animal, hydrolysis method, peptide molecular weight and added ingredients.
• It did not address interactions with medications, because the reviewed trials were not designed as interaction studies (Journal of Drugs in Dermatology, 2019).

Gastrointestinal complaints: What Studies Report

Where side effects are discussed in the oral collagen literature, they are most often described as mild digestive complaints — a sense of fullness, altered stool, or an unpleasant taste associated with the powder. The systematic review of dermatological applications of oral collagen supplementation did not identify adverse events across the trials it pooled (Journal of Drugs in Dermatology, 2019), which means the published dermatology record offers no quantified incidence figures for gastrointestinal symptoms to summarise. Readers looking for such numbers should note that their absence reflects how the trials reported their results, not proof that no participant ever experienced discomfort.

A broader review of nutricosmetics — orally ingested products marketed for skin, hair and nail benefits — placed collagen among the ingredients used in this category and discussed the regulatory and evidence context in which such products are sold (Phytotherapy Research, 2019). That context is relevant to side-effect questions because finished supplement products may contain flavourings, sweeteners, vitamins or botanical extracts in addition to the collagen peptide itself, and a complaint reported by a consumer cannot be attributed to the peptide alone.

Joint and tendon trials: What Studies Report

The joint literature is where safety has been named explicitly as a study objective. A randomised, double-blind, placebo-controlled trial examined the efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis, with safety stated in the study's own framing as a co-equal endpoint alongside efficacy (Frontiers in Nutrition, 2025). Trials in symptomatic populations matter for a safety page because participants are older on average than cosmetic-trial volunteers and are more likely to be taking analgesics and other medications.

A systematic review and meta-analysis of dietary supplements for osteoarthritis assessed a range of ingredients, including collagen derivatives, and the researchers emphasised methodological limitations across the underlying trials, including small sample sizes and short follow-up (British Journal of Sports Medicine, 2018). Those limitations constrain safety conclusions as much as efficacy conclusions: a body of small, short trials cannot rule out uncommon harms.

In the tendon literature, a trial combined oral supplementation of specific collagen peptides with calf-strengthening exercises in Achilles tendinopathy patients and reported enhanced function and reduced pain compared with exercise alone (Nutrients, 2019). Because the supplement was studied alongside a structured exercise programme, that design cannot isolate which effects — beneficial or otherwise — belonged to the peptide.

Animal and preclinical observations: What Studies Report

Preclinical work occasionally examines organ-level outcomes that human cosmetic trials do not measure. One animal study investigated the effects of sheep bone collagen peptide on liver lipid deposition in ovariectomised rats (Journal of Nutritional Science and Vitaminology, 2022). Animal findings of this kind are not evidence of harm or benefit in people; species, dose scaling, hormonal status and the specific peptide source all differ from the human trial setting, and the researchers studied a defined rodent model rather than human liver outcomes.

How the trials compare

Populations the published trials did not cover

Reported tolerability applies to who was enrolled. Across the verified human literature summarised here, participants were adult volunteers recruited for skin endpoints or adults with knee osteoarthritis or Achilles tendinopathy (Frontiers in Nutrition, 2025), (Nutrients, 2019). The published abstracts in this set did not describe trials in pregnancy or lactation, in children or adolescents, or in people with chronic kidney or liver disease. They also did not report structured testing for allergic reactions related to the animal source of the collagen — bovine, porcine, marine or other — which is a question a consumer with a known food allergy would reasonably raise with a clinician rather than resolve from this literature.

Limits of the safety evidence

1. Short duration. The trials summarised here ran over defined supplementation windows measured in weeks to months (Skin Pharmacology and Physiology, 2014), (Nutrients, 2018), so multi-year safety was not assessed.
2. Small samples. The osteoarthritis meta-analysis specifically flagged small trial sizes and methodological quality as constraints on interpretation (British Journal of Sports Medicine, 2018).
3. Product heterogeneity. Collagen preparations differ in source, molecular weight and formulation, and the nutricosmetics review discussed the varied regulatory landscape for orally ingested cosmetic products (Phytotherapy Research, 2019).
4. Publication emphasis. When a study's primary aim is a cosmetic endpoint, adverse events may be summarised in a single sentence, which limits how much detail is available (Journal of Drugs in Dermatology, 2019).

Taken together, the published record describes collagen peptides as well tolerated in the specific trial settings studied, while leaving long-term, special-population and interaction questions unanswered. Nothing on this page is a recommendation, and decisions about supplement use belong with a licensed clinician who knows an individual's medical history.

References

• Oral Collagen Supplementation: A Systematic Review of Dermatological Applications (Journal of Drugs in Dermatology, 2019)
• Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study (Skin Pharmacology and Physiology, 2014)
• Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin: A Randomized, Double-Blind, Placebo-Controlled Study (Nutrients, 2018)
• Low-molecular-weight collagen peptides supplement promotes a healthy skin: A randomized, double-blinded, placebo-controlled study (Journal of Cosmetic Dermatology, 2024)
• Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis (British Journal of Sports Medicine, 2018)
• Skin Anti-Aging and Moisturizing Effects of Low-Molecular-Weight Collagen Peptide Supplementation in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (Journal of Microbiology and Biotechnology, 2025)
• Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial (Frontiers in Nutrition, 2025)
• Nutricosmetics: A brief overview (Phytotherapy Research, 2019)
• Oral intake of collagen peptide NS improves hydration, elasticity, desquamation, and wrinkling in human skin: a randomized, double-blinded, placebo-controlled study (Food & Function, 2023)
• Oral Supplementation of Specific Collagen Peptides Combined with Calf-Strengthening Exercises Enhances Function and Reduces Pain in Achilles Tendinopathy Patients (Nutrients, 2019)
• Oral Supplementation of Low-Molecular-Weight Collagen Peptides Reduces Skin Wrinkles and Improves Biophysical Properties of Skin: A Randomized, Double-Blinded, Placebo-Controlled Study (Journal of Medicinal Food, 2022)
• Effects of Sheep Bone Collagen Peptide on Liver Lipid Deposition in Ovariectomized Rats (Journal of Nutritional Science and Vitaminology, 2022)